Department of Health and Ageing and MSAC logos
image of a microscope

Application 1003

OctreoScan® scintigraphy for gastroentero-pancreatic neuroendocrine tumours

Application No.

1003

Application NameOctreoScan® scintigraphy for gastroentero-pancreatic neuroendocrine tumours
Advisory PanelDr Richard King
(Chair and MSAC member)
Dr Terri Jackson
(MSAC member)
Dr Michael Kitchener
(MSAC member)
Dr Rodney Hicks
(co-opted member)
Date Received by MSAC Secretariat1 January 1997
Stage 1 - EligibilityEligible
Stage 2 - AssessmentCompleted
Stage 3 - Formulation of Advice to the MinisterThis assessment was considered by the MSAC at the 19 May 1999 meeting.

Public funding should be supported for this diagnostic test:
  • where there is suspected gastroentero-pancreatic neuroendocrine tumour, based on biochemical evidence, with negative or equivocal structural imaging from conventional radiology (CT or MRI); or
  • where surgically amenable disease has been identified, based on biochemical evidence and conventional imaging, in order to rule out further metastatic disease. Since there is currently insufficient evidence pertaining to the use of OctreoScan for the purposes of determining whether octreotide therapy is a viable therapeutic option, public funding should not be supported at this time for this use.
Stage 4 - DecisionEndorsed by the Minister for Health and Ageing 9 August 1999
Stage 5 - Implementation